CV Therapeutics reiterated by Merrill at buy

CV Therapeutics Inc. was reiterated by Merrill Lynch analyst Ben Li at a buy rating with a price target on the stock of $33 per share following news that the company and U.S. co-marketing partner Solvay Pharmaceuticals received approval of Aceon for the treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction - a new indication for the drug, which is currently marketed for the treatment of hypertension. CV Therapeutics shares Wednesday were up $0.34, or 1.26%, at $27.28 on volume of 1,144,578 shares versus the three-month running average of 885,417 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.